BeOne Medicines (BEIGF) Net Cash Flow (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Net Cash Flow data on file, last reported at $224.5 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $224.5 million, up 301.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 995.0% YoY), and the FY2025 annual result was $1.9 billion, up 485.62% from the prior year.
• Net Cash Flow slipped to $224.5 million in Q1 2026 per BEIGF's latest filing, from $475.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $1.3 billion in Q3 2025 and troughed at -$390.0 million in Q4 2022.
• A 5-year average of $30.6 million and a median of -$37.4 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow sank 815.09% in 2023, then surged 2172.2% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$390.0 million in 2022, then surged by 116.11% to $62.8 million in 2023, then plunged by 136.56% to -$23.0 million in 2024, then surged by 2172.2% to $475.9 million in 2025, then slumped by 52.84% to $224.5 million in 2026.
• Business Quant data shows BEIGF's Net Cash Flow at $224.5 million in Q1 2026, $475.9 million in Q4 2025, and $1.3 billion in Q3 2025.